LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...
Wockhardt’s experimental drug, Zaynich, has shown impressive results, achieving a 100% cure rate in clinical trials for ...
Environmental toxins like pesticides and heavy metals can lead to blood cancer. Learn how genetics, lifestyle, and exposure ...
Acute Myeloid Leukaemia (AML) with Retinoic acid receptor-gamma (RARG) fusions have similarities to Acute Promyelocytic Leukemia (APL) but are not responsive to standard APL treatments.
1Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...
Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...
Vevoctadekin is under clinical development by Simcha Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.
The term “cure” is rarely used, however, as cancer can come back. National Cancer Institute. Adult lymphoblastic leukemia treatment (PDQ): health professional version. National Cancer Institute. Adult ...
18, 2024 — Researchers have developed an in vitro cancer model to investigate ... scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth.